Eucrisa (crisaborole) / Pfizer - LARVOL DELTA

Comparative risk of infections in children with atopic dermatitis who started dupilumab vs. topical therapies: a nationwide propensity-score matched cohort study (AAD 2026) - "The exposure was dupilumab and the comparator was advanced topical agents (calcineurin inhibitors, crisaborole, ruxolitinib)...In adolescents, dupilumab was associated with reduced risks of SSTI (RR, 0.76; 0.58–1.00) and other infections (RR, 0.84; 0.70–0.99). Conclusion In this large real-world cohort, dupilumab use in adolescents with atopic dermatitis was associated with lower 6-month infection risks, particularly for SSTI, compared with advanced topical therapy."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease

Topical PDE4 Inhibition with Crisaborole Alters Skin Microbiome Composition in Atopic Dermatitis (AAD 2026) - "While crisaborole was not directly antimicrobial, the enrichment of skin commensals suggests it may help promote a balanced skin microbiome. Further studies are warranted to clarify these interactions and guide strategies targeting both inflammation and microbial dysbiosis."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Effectiveness of 308-nm Excimer Light with Pimecrolimus and Crisaborole in Pediatric Vitiligo: A Retrospective Study. (PubMed, Clin Cosmet Investig Dermatol) - "The combination of 308-nm excimer light therapy with topical pimecrolimus cream and crisaborole ointment demonstrates favorable efficacy in pediatric vitiligo, with only mild and well-tolerated adverse reactions. The integrated use of dermatoscopy, ImageJ software, Wood's lamp examination, and a color difference meter provides an objective, quantitative, and reproducible approach for digitally documenting changes in lesion color and area before and after vitiligo treatment."

Journal • Retrospective data • Dermatology • Immunology • Pediatrics • Vitiligo

Crisaborole Reduced the Staphylococci but Increased Cutibacterium on the Skin Microbiome of Children with Atopic Dermatitis. (PubMed, Dermatitis) - "Although the efficacy of crisaborole in treating mild-to-moderate AD in children is not equivalent to that of TCS, crisaborole could still remarkably improve the clinical symptoms of patients and partially restore the microbial diversity on the skin surface of children with AD."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

When the Usual Fails: Severe Eczema in a Syndromic Patient Resistant to Conventional Therapy (AAD 2026) - "This case highlights the successful use of dupilumab in a very young infant with RTS and treatment-resistant AD...Topical therapies—including high-potency corticosteroids, crisaborole, and off-label tacrolimus—failed to provide meaningful clinical improvement...The case raises important questions about potential immune dysregulation in RTS and suggests biologic therapy may be a viable and safe option in syndromic infants with recalcitrant AD. Further study is needed to understand the immunologic profile of RTS and its relationship to atopic disease."

Clinical • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Developmental Disorders • Fibrosis • Genetic Disorders • Immunology • Inflammation • Mental Retardation • Pruritus • Sleep Disorder

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

COMPARING 1.5% RUXOLITINIB CREAM AND OTHER THERAPIES FOR PEDIATRIC PATIENTS WITH ATOPIC DERMATITIS: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS (ISPOR 2026) - "For each outcome, all treatments for which outcome data were reported, apart from dupilumab + TCS, could be connected in a network to 1.5% ruxolitinib cream through a common comparator (vehicle). Results of NMAs indicate 1.5% ruxolitinib cream offers similar or better disease control than that of available topical therapies for pediatric AD based on IGA-TS, EASI-75, and Itch NRS4 and similar safety in terms of TEAEs."

Retrospective data • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Comparison chart: Topical nonsteroidal drugs for atopic dermatitis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Advanced Topical Nonsteroidal Therapies for Atopic Dermatitis: Consensus Statements from an Expert Panel. (PubMed, J Drugs Dermatol) - "Advanced topical nonsteroidal therapies represent an important evolution in AD management and are appropriate first-line options across disease severities, supporting sustained disease control and improved quality of life."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Innovation in pediatric atopic dermatitis care: examining emerging topical treatment options. (PubMed, Expert Rev Clin Pharmacol) - "This manuscript will describe recent innovations in topical, steroid-sparing therapies for pediatric AD, highlighting emerging agents such as roflumilast, ruxolitinib, and tapinarof, as well as investigational therapies...First-line therapies include topical corticosteroids, topical calcineurin inhibitors, and the phosphodiesterase-4 inhibitor crisaborole, all of which have demonstrated efficacy but are limited by safety considerations, tolerability, and acceptability for long-term use. In recent years, novel topical agents with distinct mechanisms of action have expanded the therapeutic landscape, representing important steroid-sparing alternatives for children with AD. Emerging topical therapies for pediatric AD demonstrate substantial promise in addressing longstanding unmet needs, but long-term safety and practice-based effectiveness data remain critical for optimizing care."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pediatrics • Pruritus

Treatment of discoid lupus erythematosus with crisaborole. (PubMed, J Dermatolog Treat) - "The patient was treated with topical crisaborole 2% ointment once daily in combination with hydroxychloroquine. Crisaborole, a topical phosphodiesterase-4 inhibitor approved for atopic dermatitis, may represent a well-tolerated nonsteroidal therapeutic option for facial DLE, particularly in patients who are unresponsive to or intolerant of conventional treatments. Further studies are needed to clarify its efficacy and long-term safety in DLE."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Discoid Lupus Erythematosus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus

Sequential Small-Molecule Therapy for Lymphocytic Cicatricial Alopecia: A Multicenter Prospective Cohort Pilot Study. (PubMed, J Am Acad Dermatol) - "In this patient cohort, three-stage sequential regimen was well tolerated and offers a promising treatment option for active LCA."

Journal • Alopecia • Immunology • Lichen Planus • Rare Diseases

Crisaborole as a Potential Treatment for Pediatric Alopecia Areata: A Case Report and Literature Review. (PubMed, Cureus) - "Crisaborole's safety profile, with minimal systemic absorption, makes it a promising non-corticosteroidal alternative for pediatric patients. This case suggests that crisaborole may be an effective treatment for pediatric AA, but further studies with larger sample sizes and longer follow-up periods are needed to validate these findings."

Journal • Alopecia • Immunology • Inflammation • Pediatrics

Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (clinicaltrials.gov) - P4 | N=148 | Not yet recruiting | Sponsor: Hayat Abad Medical Complex, Peshawar

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

CRISA-AD: Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema (clinicaltrials.gov) - P4 | N=270 | Not yet recruiting | Sponsor: Jinnah Postgraduate Medical Centre

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Maternal and Pediatric Precision in Therapeutic Knowledge Portal (MPRINT-KP): Landscape Analysis of Pharmacology Research in Maternal and Pediatric Patient Populations. (PubMed, Pharmacotherapy) - "In pediatric patients, there were crisaborole-associated hemorrhage and moxifloxacin-associated cardiac toxicities. In pregnant women, the analysis revealed terconazole-associated abnormalities of heartbeat; benzonatate-associated depressive and anxiety disorders; buspirone-associated abnormalities of heartbeat; cyclobenzaprine-associated tubulo-interstitial nephritis; and pantoprazole-associated hearing loss and voice and resonance disorders. For the first time, a large-scale landscape analysis of pharmacotherapy knowledge gap in both maternal and pediatric patient populations was conducted and identified new drug associated ADE evidence using real world data."

Journal • Review • CNS Disorders • Hematological Disorders • Mood Disorders • Nephrology • Otorhinolaryngology • Pediatrics • Psychiatry

Standardising the diagnosis and management of atopic dermatitis in India: A consensus statement by the modified Delphi method by IADVL Special Interest Group of Pediatric Dermatology (STAND AD). (PubMed, Indian J Dermatol Venereol Leprol) - "For systemic therapy, cyclosporine remains first-line for moderate-to-severe AD, with conditional recommendations for methotrexate, mycophenolate, and JAK inhibitors such as abrocitinib. Emerging therapies like topical tofacitinib and crisaborole were discussed with caution due to limited Indian data. Limitation Although several new therapies-such as abrocitinib and dupilumab-have been approved for pediatric atopic dermatitis, consensus among Delphi panelists remains limited...It addresses previously unmet needs in adult AD. This consensus is expected to enhance clinical outcomes and standardise AD management nationally."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pediatrics

PDE4 Inhibitor-Responsive Dermatoses: An Emerging Concept in Dermatology. (PubMed, J Clin Aesthet Dermatol) - "This suggests that PDE4 inhibitors may assume a similar complementary framework for treating "PDE4 inhibitor-responsive dermatoses." Certain formulations of PDE4 inhibitors (including apremilast, crisaborole, and roflumilast) have undergone rigorous investigation in clinical trials and demonstrated robust efficacy and safety in many dermatologic conditions, achieving United States Food and Drug Administration approval for atopic dermatitis, psoriasis, and seborrheic dermatitis. Herein, we summarize the clinical evidence supporting the emerging concept of "PDE4 inhibitor-responsive dermatoses" and propose that PDE4 inhibition offers an additional pathway to achieving desired clinical outcomes."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • Seborrheic Dermatitis

Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (clinicaltrials.gov) - P4 | N=30 | Not yet recruiting | Sponsor: Cairo University

New P4 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Exploring the Therapeutic Potential of Crisaborole Gel in Atopic Dermatitis: A Review. (PubMed, Recent Adv Drug Deliv Formul) - "Crisaborole's specific mechanism, safety profile, and effectiveness in interrupting the inflammatory cycle make it an attractive treatment alternative, according to this study. Crisaborole is presented here as a potential remedy to address the research gap: the need for safer, more efficient therapies that target inflammatory pathways in AD."

Journal • Allergic Rhinitis • Allergy • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Pediatrics • Pruritus • Pulmonary Disease • Respiratory Diseases • FLG

Hydroxypropyl-β-cyclodextrin co-delivery hydrogel of crisaborole and curcumin for combinational antioxidant/anti-inflammatory therapy of vitiligo. (PubMed, Mater Today Bio) - "In vivo, Cri/Cur@CD-Gel achieved significant repigmentation in monobenzone-induced vitiligo mice, markedly reducing epidermal ROS, CD8+ T-cell infiltration, and inflammatory cytokines (TNF-α, IL-1β, and IL-6). This study demonstrates that the combination of HP-β-CD-based encapsulation and carbomer hydrogel delivery serves as a potential topical administration platform for co-delivering hydrophobic crisaborole and curcumin, and establishes a promising strategy to alleviate vitiligo, that concurrently addresses oxidative damage, inflammatory responses, and melanocyte regeneration."

Journal • Dermatology • Immunology • Inflammation • Vitiligo • CD8 • IL1B • IL6 • TNFA • Tyrosinase

Recent advances in the synthesis and applications of oxaborole derivatives. (PubMed, Org Biomol Chem) - "This property has led to the successful development of FDA-approved therapeutics such as tavaborole (antifungal) and crisaborole (anti-inflammatory), sparking widespread research interest. Emphasis is placed on the development of sustainable and efficient routes, such as photocatalytic, mechanochemical, and continuous-flow processes. Along with the synthesis, the review also covers the expanding applications of these compounds in different fields."

Journal • Review

Benzoxaborole and Beyond: The Emergence of Cyclic Hemiboronic Acids as a Versatile Chemotype in Medicine, Catalysis, and Materials. (PubMed, Chem Rev) - "Inspired by the recent success of the benzoxaborole ring system in drug discovery, highlighted by the approved products tavaborole and crisaborole, the last two decades have seen a continuous rise in interest toward other classes of nonaromatic and pseudoaromatic hemiboronic heterocycles. Preparative methods, structural characteristics, and important physical properties such as the open-closed equilibrium, acidity (pKa), and molecular interactions are discussed and compared between different structural subtypes. Ring size and the nature of heteroatoms within the ring often exert dramatic differences in acidity, reactivity, and aromatic character of the heterocycle, which in turn enable their methodical application."

Journal • Review

Recent Advancements in the Diversification and Applications of Boron-Containing Compounds in Medicinal Chemistry. (PubMed, Pharmaceuticals (Basel)) - "Boron-containing compounds have made a significant impact on the field of medicinal chemistry since the discovery of Bortezomib (Velcade®), a dipeptide boronic acid approved by the FDA in 2003 for the treatment of multiple myeloma. Since then, over the last two decades, four more boron-containing drugs have been approved by the FDA: Tavaborole (Kerydin®), Ixazomib (Ninlaro®), Crisaborole (Eucrisa®), and Vaborbactam (in Vabomere®). These compounds are approved for treating conditions such as onychomycosis, multiple myeloma, and atopic dermatitis, as well as an Aβ-lactamase inhibitor approved in combination with meropenem for treating infections...This review aims to highlight the recent advances made in the last decade in the drug design of boron-containing compounds and their therapeutic applications. Here, in this work, we have focused on the recent diversification and progress of boron-containing compounds in medicinal chemistry applications."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Hematological Malignancies • Immunology • Infectious Disease • Multiple Myeloma • Oncology